Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML 01/99: FLAG-Ida and Consolidation Therapy in AML
NCT00209833Phase 3Unknown
- Sponsor
- Hannover Medical School
- Start
- Jan 1999
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of fludarabine, cytarabine, idarubicin, filgrastim, daunorubicin in acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (RAEB-T), sponsored by Hannover Medical School. Status: unknown.
02
Drugs
fludarabinecytarabineidarubicinfilgrastimdaunorubicin
03
Conditions
acute myeloid leukemia (AML)refractory anemia with excess blasts in transformation (RAEB-T)
Beyond the preview
Go deeper on NCT00209833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209833.